FDA hits CDMO Kolmar Korea with warning letter over manufacturing issues

fda
The FDA issued a warning letter to CDMO Kolmar Korea, citing significant GMP issues. (FDA)

The FDA issued a warning letter to Korean contract drug manufacturer Kolmar Korea, citing significant GMP issues stemming from an inspection conducted last September.

In a letter posted to the regulatory agency’s website, the FDA said inspectors found that the company failed to investigate out-of-specification results for certain lots of an over-the-counter cream and instead retested and invalidated the OOS results without justification.

Additionally, FDA inspectors said Kolmar Korea didn’t follow its own written procedures for document control, which require quality control unit approval for discarding records.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“Our investigator observed documents and records, including batch production records, certificates of analysis, and laboratory worksheets, that were torn and discarded without documented quality unit approval,” according to the FDA letter.

Earlier this year, Kolmar Korea beat out private equity firms to snap up health foods and drugmaker CJ HealthCare, the maker of a popular South Korean anti-hangover drink, for $1.2 billion.

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.